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Abstract
The implication of soluble Abeta in the Alzheimer’s disease (AD) pathology is
currently accepted. In fact, the content of soluble extracellular Abeta species, such
as monomeric and/or oligomeric Abeta, seems to correlate with the clinico-
pathological dysfunction observed in AD patients. However, the nature (monomeric,
dimeric or other oligomers), the relative abundance, and the origin (extra-/
intraneuronal or plaque-associated), of these soluble species are actually under
debate. In this work we have characterized the soluble (defined as soluble in Tris-
buffered saline after ultracentrifugation) Abeta, obtained from hippocampal samples
of Braak II, Braak III–IV and Braak V–VI patients. Although the content of both
Abeta40 and Abeta42 peptides displayed significant increase with pathology
progression, our results demonstrated the presence of low, pg/mg protein, amount
of both peptides. This low content could explain the absence (or below detection
limits) of soluble Abeta peptides detected by western blots or by
immunoprecipitation-western blot analysis. These data were in clear contrast to
those published recently by different groups. Aiming to explain the reasons that
determine these substantial differences, we also investigated whether the initial
homogenization could mobilize Abeta from plaques, using 12-month-old PS1xAPP
cortical samples. Our data demonstrated that manual homogenization (using
Dounce) preserved the integrity of Abeta plaques whereas strong homogenization
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procedures (such as sonication) produced a vast redistribution of the Abeta species
in all soluble and insoluble fractions. This artifact could explain the dissimilar and
somehow controversial data between different groups analyzing human AD
samples.
Introduction
Progressive aggregation and accumulation of extracellular amyloid-b (Abeta)
peptides is central to Alzheimer’s disease (AD) pathogenesis [6]. Multiple Abeta
oligomers, ranging from low-molecular weight oligomers to protofibrils and
fibrils, apparently coexist in the brain tissue. However, the exact nature of these
toxic aggregated Abeta peptides and their origin (intra- or extraneuronal or even
plaque-derived) remains speculative. After the initial investigation by Podlisny et
al. [15], a growing number of evidences strongly indicate that soluble Abeta
forms, rather than insoluble species, including amyloid plaques, are the main toxic
species associated with AD (see [1] and [5], for recent reviews). Subsequent
studies by different independent groups, in an attempt to identify the precise
soluble form that best correlated with cognitive impairment, have in fact reported
a remarkable diversity of soluble aggregates in the interstitial fluid of human AD
and transgenic model brains. Based on in vitro, using synthetic Abeta peptides, or
‘‘in vivo’’ experiments, different soluble Abeta oligomers, ranging from dimers to
high-molecular weight aggregates (such as 12-mer, 24-mer, 32-mer, 150-mer)
have been identified as the putative neurotoxic agents, disturbing the
neurotransmission and causing neuronal death (see table 1 from [1]). The reasons
for this apparent heterogeneity are not known but could derive from the different
aggregation protocols of synthetic Abeta (for instance see [2] and [11]), the
different transgenic models used or the different brain regions characterized. In
this sense, it is particularly intriguing the quantitative and qualitative differences
between soluble Abeta isolated by microdialysis and by homogenization-
centrifugation approaches, reported even by the same group [24].
Perhaps more relevant is the fact that, using brain samples from Alzheimer
patients, a great disparity in the nature and quantities of soluble Abeta has been
observed. For instance, relatively large amounts of monomeric and dimeric
soluble Abeta (identified by western blots) have been reported by some groups
[3, 12, 13, 17, 23, 24] whereas others found small amounts (pg range, detected by
dot blots or sensitive oligomeric specific ELISA assays) of soluble Abeta [4, 21].
Among multiple causes, these differences between groups could reflect the absence
of a unified isolation protocol for the extraction and characterization of soluble
Abeta. In fact, many different homogenization (from manual to sonication) and
centrifugation protocols have been used to isolate a theoretically similar
extracellular soluble fraction. Considering that Abeta plaques constitute a large
reservoir of different Abeta species, and that their number increased with the
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pathology, strong homogenization protocols could indeed disturb the stability of
plaques, and cause the release of different Abeta species. However, few (if any)
control experiments were carried out to determine the extent of plaque disruption
due to the isolation procedure.
In the present study, we analysed the Abeta content in the soluble fractions of
the hippocampus from human AD autopsy samples and transgenic models in
order to investigate the possible repercussion of the homogenization protocols in
the soluble fraction preparation. For that, we have directly compared the effect of
homogenization using gentle conditions with sonication at different intensities.
We concluded that strong homogenization, such as sonication, produced the
release of Abeta peptides from Abeta plaques to soluble fractions.
Materials and Methods
Antibodies
82E1 and anti-soluble APPalpha antibodies were purchased from Immuno
Biological Laboratories (IBL). 6E10 antibody was provided by Signet Laboratories.
Anti-LC3B and anti-ATP synthase-beta were purchased from Cell Signaling
Laboratories and BD Transduction Laboratories, respectively. Anti-mouse or anti-
rabbit horseradish-peroxidase-conjugated secondary antibodies were purchased
from Dako Denmark.
Human samples
The study was performed using 30 cases obtained from the BTIN-Tissue Bank for
Neurological Research (Madrid, Spain) and from the Neurological Tissue Bank of
IDIBELL-Hospital of Bellvitge (Barcelona, Spain), approved by the committee for
human and animal use for research at Seville and Malaga Universities, Spain. The
cases were scored for Braak stage for neurofibrillary tangles (II–VI). In Table 1 are
detailed the age, Braak stage, sex and the delay post-mortem before the extraction
of the samples.
Preparation of human brain lysates
Soluble (S1) fractions were prepared as described previously [9, 10, 19, 22]. Briefly,
frozen human hippocampal tissue was homogenized (1/5 w/v) using a manual
Dounce homogenizer (10 strokes using pestle A (large clearance:
Table 1. Human samples.
mean Age ¡ SD Sex Delay post-mortem mean h ¡ SD BRAAK
84.0¡5.47 7 male - 4 female 6.2¡4.5 II
78.1¡11.99 4 male - 3 female 5.76¡5.44 III–IV
80.4¡10.21 4 male - 8 female 11.2¡4.0 V–VI
doi:10.1371/journal.pone.0114041.t001
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0.114¡0.025 mm) and 10 strokes using pestle B (small clearance:
0.05¡0.025 mm), in Tris-buffered saline (TBS; 20 mM Tris-HCl, 140 mM NaCl,
pH 7.5) containing protease and phosphatase inhibitors (Roche). Homogenates
were then ultracentrifuged (4 C˚ during 60 min) at 100,0006g (TLA110 rotor,
Optima MAX Preparative Ultracentrifuge, Beckman Coulter). The supernatant,
which constitutes the S1 fractions, was collected, aliquoted and stored at 280 C˚
for further use. The remaining pellet (P1) was stored at 280 C˚ until needed.
Sequential protein extraction
For sequential extraction experiments, the P1 fraction was first resuspended (by
Dounce homogenization; 10 strokes using pestle B) in RIPA buffer (1% CHAPS,
1% deoxycholate, 0.2% SDS, 140 mM NaCl, 10 mM Tris-HCl, pH 7.4, containing
protease and phosphatase inhibitors), incubated for 30 min at 4 C˚ with agitation,
and centrifuged at 30,0006g for 30 min at 4 C˚. The supernatant constituted the
S2 fraction. The pellet from this centrifugation was sequentially extracted (by
incubating during 30 min, 4 C˚ followed by centrifugation 30,0006g for 30 min)
using buffered-SDS 2% (2% SDS in 20 mM Tris-HCl, pH 7.4, 140 mM NaCl) (S3
fraction) and 4% SDS plus 8 M urea (P3 fraction). All isolated fractions were
aliquoted and stored at 280 C˚ until use.
Abeta quantification by sandwich ELISA
The amount of soluble Abetax-40 or Abetax-42 peptides was determined in
human soluble S1 fractions, using commercial sandwich ELISA (Human Abx-40
ELISA Kit, Invitrogen; Amyloid beta x-42 ELISA, DRG) following the
manufacturer recommendations. For these experiments equivalent amount of
proteins, from the different S1 fractions isolated from Braak II to Braak V–VI
samples, were pooled. For each assay, 25 mg of protein from the pooled-soluble
fractions was used. The ELISA experiments were repeated four times, in
independent experiments, using duplicate or triplicate replicas.
For oligomeric ELISA, we used 6E10-6E10 antibody pairs in conjunction with
the Alpha-Lisa technology, developed by Perkin Elmer. This assay recognized
synthetic Abeta dimer, used as standards, whereas synthetic monomeric Abeta42
produced no signal over the background. The lower limit sensitivity of this assay
was 0.02 pg/ml.
Preparation of PS1delta9xAPPswe cortical fractions
All animal experiments were performed in accordance with the guidelines of the
Committee of Animal Research of the University of Seville (Spain), University of
Malaga (Spain) and the European Union Regulations.
B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J (PS1xAPP) transgenic model was
maintained in C57BL/6 genetic background for several generations (F10). Cortical
samples from 12 months PS1xAPP transgenic mice were homogenized in TBS (1/
10 w/v) containing protease and phosphatase inhibitor-cocktail (Roche), using
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two different approaches: a) manual Dounce homogenizer (10 strokes with pestle
A and 10 strokes with pestle B) or b) sonication (100 W ultrasonic processor
UP100 H, Hielscher) for x4 or x8, 15 sec pulses at 4 C˚.
After homogenization, the different fractions were isolated as described in [17].
Briefly, homogenates were first centrifuged at 14,0006g (30 min, 4 C˚). The
supernatant (containing soluble and microsomal fraction) was then ultracen-
trifuged at 100,0006g (60 min, 4 C˚) using a TLA110 rotor (Optima MAX
Preparative Ultracentrifuge, Beckman Coulter). The supernatant of this
ultracentrifugation constituted the TBS soluble fraction. The pellet, that
constituted the microsomal fraction, was resuspended in TBS.
On the other hand, pellets from the first centrifugation (membranes plus Abeta
plaques) were sequentially solubilized using 2% buffered-SDS followed by SDS-
Urea (4% SDS plus 8 M urea).
PS1xAPP sequential protein extraction
For these experiments, 12-month-old PS1xAPP cortical tissue was used. The TBS
soluble fraction was isolated by ultracentrifugation as described above. For the
sequential detergent-based extraction, the ultracentrifugation pellets were
sequentially extracted using 2% CHAPS (in TBS), RIPA buffer, 2% SDS and
finally 4% SDS-8 M urea. For each detergent treatment pellets were resuspended
in the appropriate media, incubated for 30 min at 4 C˚ and centrifuged at
30,0006g (30 min, 4 C˚). All fractions were stored at 280 C˚ for further use.
Western blots
Western blots were performed as described previously [9, 10, 19, 22]. Briefly, for
Abeta peptides, 10–20 mg (unless stated in text) of protein from the different
samples were loaded on 16% SDS-Tris-Tricine-PAGE and transferred to PVDF
(Immobilon-P Transfer Membrane, Millipore). For sAPPalpha, LC3 and
ATPsynthase, 12% SDS-Tris-Glicine-PAGE was used and transferred to
nitrocellulose (Optitran, GE Healthcare Life Sciences).
Membranes were then blocked using 2% low-fat milk in TPBS (0.1% Tween-20,
137 mM NaCl, 2.7 mM KCl, 10 mM phosphate buffer, pH 7.4) and incubated
overnight, at 4 C˚, with the appropriate antibody. The membranes were then
incubated with anti-mouse or anti-rabbit horseradish-peroxidase-conjugated
secondary antibody (Dako) at a dilution of 1/10,000. The blots were developed
using the Pierce ECL 2 Western Blotting Substrate detection method (0.5 pg,
lower limit sensitivity; Thermo Scientific). The images were obtained with the
luminescent image analyzer Image Quant LAS4000 mini (GE Healthcare Life
Sciences) and then analyzed using PCBAS program.
RNA extraction, retrotranscription and real-time RT-PCR
Total RNA was extracted from cells (line N13) using Tripure Isolation Reagent
(Roche). After isolation the RNA integrity was determined, by agarose gel
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electrophoresis, resulting comparable in all samples. Total RNA was determined
by spectrophotometric measures.
Retrotranscription (RT) was performed using 4 mg of total RNA as template
and High-Capacity cDNA Archive Kit (Ref.4368813, Applied Biosystems)
following the manufacturer recommendations. For real time RT-PCR, 40 ng of
cDNA were mixed with 2x Taqman Universal Master Mix (Ref.4369016, Applied
Biosystems) and 20x Taqman Gene Expression assay probes (TNFalpha,
Mm00443258_m1; IL1beta, Mm00434228_m1; IL6 Mm00446190_m1; GAPDH,
Mm99999915_g1; 18s, Mm03928990; beta-actin, Mm00607939_s1; Applied
Biosystems). PCR reactions were carried out in 96 well plates using either ABI
Prism 7000 or 7900HT sequence detector systems (Applied Biosystems). The RT-
PCR conditions included two initial steps of 2 min at 50 C˚ to activate the
polymerase followed by 10 min at 95 C˚, and the subsequent 40 cycles of
denaturation (95 C˚, 15 sec) and annealing (60 C˚, 1 min). The cDNA levels of the
different samples were determined using GAPDH as housekeeper. Similar results
were obtained using beta-actin or 18s rRNA (not shown). The amplification of the
housekeeper was done in parallel with the gene to be analyzed, showing a similar
amount of cDNA in all tested samples. All our data are expressed as the mean of at
least three different measures [9], [10], [19], [22].
Amyloid plaque isolation
Beta-amyloid plaques were isolated as described [18]. PS1xAPP (12 months of
age) cortical samples were homogenized using Dounce as above and centrifuged at
2,0006g for 30 min (4 C˚). The supernatant was further centrifuged for 1 hour at
20,0006g to collect the pellet, enriched in amyloid beta plaques. This pellet was
resuspended in PBS, layered over a discontinuous sucrose gradient (0.4 ml of
1.0 M; 0.4 ml of 1.2, 0.8 ml of 1.4 and 0.4 ml of 2.0 M sucrose in PBS, pH 7.4)
and centrifuged at 100,0006g (Optima MAX Preparative Ultracentrifuge,
Beckman Coulter) for 1 h at 4 C˚ using a TLS-55 swing rotor. Then, fractions
(from top) were removed and the 1.4–2.0 M sucrose interphase (enriched in
amyloid plaques) was collected and diluted in PBS. The enriched amyloid fraction
was centrifuged at 100,0006g for 1 h at 4 C˚, and the pellet was collected and
resuspended in PBS pH 7.4. The sample was separated in two aliquots, one was
Dounce homogenated and the other one was subjected to sonication (8 pulses of
15 seconds). The two samples were centrifuged at 100,0006g for 1 h at 4 C˚, and
the supernatant and pellet were collected.
N2a cultures and cell survival
N2a cells were plated at 25,000 cells/cm2 and cultured in high glucose DMEM
(Biowest)/OptiMEM (Gibco) (50–50%) supplemented with 2 mM glutamine
(Biowest) and 5% (v/v) foetal bovine serum (Biowest) in the presence of penicillin
(Biowest) and streptomycin (Biowest) (100 units/ml and 0.01 mg/ml, respec-
tively) at 37 C˚ and 5% CO2. For survival experiments, the medium was changed
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to high glucose DMEM and serum-deprived. The cells were then treated with
different amounts of TBS fractions, from Dounce or sonication homogenization,
during 24 hours. The cells survival was assayed by Flow Cytometry using the
apoptosis detection kit ANNEXIN V-FITC (Immunostep).
N13 culture and stimulation
The N13 microglial cells were plated at 15,000 cells/cm2 and cultured in RPMI
1640 (Biowest) supplemented with 2 mM glutamine (Biowest) and 5% (v/v)
foetal bovine serum (Biowest), in the presence of 100 U/ml penicillin and 100 mg/
ml streptomycin (Biowest) at 37 C˚ and 5% CO2. Cells were treated with different
amounts of TBS soluble fractions, from Dounce or sonication, during 3 hours.
Then, they were collected to isolate RNA. As controls, N13 cells were treated with
equivalent volume of PBS.
Statistical analysis
Normality of data was first assessed by using Kolmogorov-Smirnov test. Normally
distributed data were expressed and represented as mean ¡ SD. For normally
distributed data, means were compared using ANOVA followed by Tukey test
(more than two groups) or t-test (for two group comparisons).
Results
Low content of soluble Abeta oligomeric in AD patients
hippocampal formation
We have first analyzed the Abeta content of soluble fractions prepared from the
hippocampal formation (hippocampus proper, subiculum and entorhinal cortex),
using Dounce homogenization and ultracentrifugation (see also [9, 10, 19, 22]), of
AD (Braak stage V–VI) and non-demented control (Braak stages II to IV) age-
matched autopsy samples.
Quantitative analysis, using Abetax-42 or Abetax-40 sandwich ELISA (Fig. 1A),
demonstrated the presence of very small amounts (pg/mg of protein) of soluble
Abeta40-42 peptides in both AD and non-AD samples (see also [4] and [24]). In
fact, Braak II samples displayed low levels of Abeta40 whereas Abeta42 was
practically undetectable. As shown (Fig. 1A, a1 and a2), we observed a gradual
and significant increase in both soluble species, Abeta42 and Abeta40, although
more pronounced in the Abeta42 peptide, along the disease progression (3.1-fold
in Braak III–IV and 12.5-fold in Braak V–VI). In consequence, the soluble
Abeta42 peptide became equimolar with Abeta40 in demented patients (Fig. 1A,
a3). Using the Abeta40 plus Abeta42 peptide to estimate the total soluble Abeta
species, our soluble samples from AD brains contained approx 4 ng/g tissue of
soluble Abeta40-42 peptides. This value was clearly lower to that reported by
others [13].
Soluble Abeta Peptides in AD Brain
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We next attempted to characterize the Abeta species using western blots.
Importantly, neither monomeric/dimeric Abeta nor other oligomeric Abeta
species could be detected in soluble (S1, Fig. 1B) or in vesiculated (S2, Fig. 1B)
Braak VI fractions, as compared with Braak II samples. However, the monomeric-
dimeric Abeta (and probably other oligomeric forms) were clearly visible when
Abeta plaques were solubilized using 2% SDS (S3) and especially using 4% SDS/
8M urea (P3) (Fig. 1B). Furthermore, even using a large amount of proteins
(100 mg of soluble fraction, S1) in 6E10 immunoprecipitation assays (Fig. 1C), we
were unable to detect any distinctive Abeta specie in Braak V–VI, compared with
Braak II.
Taken together, these data are consistent with the existence of low levels of
soluble Abeta (pg levels), and the virtual absence of monomeric Abeta in the
Figure 1. Low soluble Abeta levels were identified in hippocampal samples from age-matched controls (Braak II and III–IV) and demented patients
(Braak V–VI). A: Soluble fractions from 11 Braak II, 7 Braak III–IV or 12 Braak V–VI samples were pooled and the Abeta x-42(a1) or x-40(a2) quantified by
sandwich ELISA. Each assay was repeated 4 times in triplicate replicas (n54 per Braak stage). Although the level of Abeta species from all samples was
low (pg/mg protein), there was a significant (showed in the figure) increased in Abetax-42 and Abetax-40 in Braak V–VI. In consequence, there was also an
increase in Abeta42/40 ratio (a3) from Braak II to Braak V–VI. B: Western blots of soluble (S1) or detergent-based extracted proteins showed the absence,
or below detection limits, of Abeta monomers or oligomers in soluble fractions. Hippocampal samples from Braak VI or Braak II individuals were sequentially
extracted in parallel. No Abeta bands were detected in S1 or CHAPS fractions. Monomeric, dimeric and other oligomeric species were clearly identified in
2% SDS and 4% SDS/8M urea samples. C: (left panel) One hundred micrograms of proteins from pooled soluble (S1) Braak II or Braak V–VI fractions were
subjected to immunoprecipitation using 6E10 antibody. The immunopellets were analyzed by western blots using 6E10 (not shown) or 82E1. No specific
bands, by comparison between Braak II and V–VI, were observed. Control experiments (right panel) demonstrated that 0.5 pg of synthetic Abeta42 could
clearly be observed by our western blot system.
doi:10.1371/journal.pone.0114041.g001
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soluble fraction of AD samples. We cannot discard the presence of minute
amounts of monomeric Abeta (below the detection limits of our western blots, 0.5
pg, see Fig. 1C) or small quantities of oligomeric Abeta, not detected by our
assays. In any case, these data are in clear contrast with those reported recently
[13, 14, 16, 17, 23].
The homogenization procedure largely determined the content of
Abeta species in the soluble fraction
While multiple reasons could explain the different levels of soluble Abeta reported
in human AD samples, the initial homogenization of the tissue could be crucial to
maintain the integrity of the Abeta plaques. A strong (aggressive) treatment of the
tissue could disrupt the aggregated Abeta from plaques and, in consequence,
contaminate all fractions with artifactual, plaque-derived, soluble Abeta species.
To evaluate this possibility, we have directly compared the effect of
homogenization using manual Dounce (see Methods) with sonication at different
intensities. As a natural rich source of human Abeta, we have used 12 month-old
cerebral cortex from PS1xAPP double transgenic mice. At this age, this model
displayed the presence of abundant Abeta plaques in the cerebral cortex (not
shown).
After homogenization, the TBS soluble fraction (equivalent to S1, see above)
and the microsomal (equivalent to the dispersible fraction reported by [16, 17])
fractions were isolated by ultracentrifugation (see Methods). The Abeta from
plaques were then extracted by sequential solubilization using 2% SDS and 4%
SDS plus 8 M urea (following [16, 17] protocol). As expected from our previous
work [10, 19, 22] (see Fig. 2A), the monomeric and oligomeric Abeta were
preferentially observed in membrane/plaque associated fractions, extracted with
2% SDS and 4% SDS/8M urea. These fractions released a relatively large amount
of monomers, dimers and other oligomeric Abeta species. However, as also
reported previously [10, 19, 22], in 6–12 months old PS1xAPP mice, these species
were absent (or below the detection limit of our western blots) in the TBS soluble
fraction or in the microsomal fraction (see Fig. 2A). The lack of oligomeric Abeta
in the TBS fraction was also probed by using a 6E10-6E10 oligomeric ELISA
(AlphaLisa, Perkin Elmer) assay (Fig. 2B). On the contrary, when the same
cortical tissue was subjected to sonication, a pulse-dependent redistribution of
Abeta in all soluble fractions was observed. As shown, the TBS soluble fraction was
contaminated with relatively high levels of monomeric Abeta (Fig. 2A).
Furthermore, we also observed the presence of different putative Abeta oligomers,
such as dimers, trimers, and low molecular weight-Abeta in these contaminated
soluble fractions (the presence of such oligomers was really high after 8 pulses of
sonication, see Fig. 2A). These Abeta oligomers were also clearly detected by
6E10-6E10 oligomeric Abeta ELISA (Fig. 2B). Similarly, the microsomal fractions
were also highly contaminated with different Abeta species. Concomitantly, we
also observed a decrease in the Abeta content from plaque rich fractions (2% SDS
and 4% SDS/8M urea extracted pellets). Therefore, sonication (even using low
Soluble Abeta Peptides in AD Brain
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Figure 2. The homogenization procedure has high impact on the integrity of Abeta plaques with the consequent solubilization and redistribution
A: Western blots, using 82E1, demonstrated the redistribution of monomeric/oligomeric Abeta species in soluble TBS or
microsomal fractions (left and middle panel) after homogenization using 4 (4P) or 8 (8P) pulses of sonication (100 watts) as compared with Dounce. This
Soluble Abeta Peptides in AD Brain
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of Abeta in different fractions.
doses) produced the redistribution of Abeta species from plaques to more soluble
fractions.
Since the oligomeric Abeta could act as either, a pro-inflammatory agent,
activating microglial cells and producing a classic immunological response [9], or
as a cytotoxic agent, producing cell death [10], we next evaluated whether the
redistribution of soluble Abeta species, due to the homogenization procedure, was
also able to modify the stimulatory and toxic properties of the soluble TBS
fractions. As shown in Fig. 2C, different amounts of Dounce-derived soluble
fractions induced absolutely no microglial response, as determined by the
expression of TNF-alpha, IL-6 and IL-1beta. However, stimulation with the TBS
soluble fraction after sonication (4 pulses) produced strong microglial activation,
characterized by the induction of the expression of all classic factors assayed.
Furthermore, we have also tested the toxicity of the soluble fractions using N2a
cells. As expected from previous work [9], the Dounce-derived TBS fraction from
12 month-old PS1xAPP produced no toxicity to N2a cells, whereas sonication-
derived fractions produced a clear toxic effect (Fig. 2D).
It could be argued that sonication was indeed releasing highly compartmen-
talized Abeta, rather than mobilizing Abeta from plaques. Thus, we next directly
tested the effect of sonication on isolated Abeta plaques. For these experiments,
plaques were isolated by ultracentrifugation on sucrose gradients and homo-
genized by Dounce or sonication. As shown, mild (Dounce) homogenization
released a limited amount of monomeric Abeta from plaques (,1% from total).
However, sonication disrupted the Abeta plaques producing (after centrifugation)
soluble monomers and, in minor extent, dimeric, trimeric and hexameric Abeta
(see Fig. 2E, longer exposure). It is noteworthy the presence of high levels of Abeta
oligomers after 4% SDS/8M urea extraction of intact plaques. However, these
oligomers were drastically reduced after sonication. Thus, sonication seemed to
induce the disaggregation and solubilization of highly aggregated Abeta from
plaques. Taken together, these data demonstrated that the homogenization
procedure was critical to maintain the integrity of Abeta plaques, and to avoid the
contamination of the different fractions with soluble Abeta species.
Next, we evaluated our isolation protocol using (in addition to anti-Abeta)
anti-soluble APPalpha antibody (as a marker of the extracellular compartment),
anti-ATPsynthase Beta (mitochondria), LC3-I (cytosol) and LC3-II (as marker for
autophagic vesicles). First, we determined the distribution of APP-derived soluble
peptides (sAPPalpha and Abeta) after serial ultracentrifugation and detergent-
increment was paralleled by a decrease on the Abeta content from 2% SDS or 4% SDS/8M urea extracted samples (right panel). This experiment was
repeated four times with similar results. B: The oligomeric Abeta content of TBS soluble fractions was also assayed using an oligomeric (6E10-6E10)
specific ELISA assay. No oligomeric Abeta was detected in Dounce prepared TBS fractions, whereas 0.28¡0.01 pg/ml of Abeta was detected after
sonication of the same cortical tissue. C–D: In vitro experiments demonstrating the stimulation of microglial cultures (C) or the toxic effect (D) of TBS soluble
fractions prepared by either Dounce or sonication. A clear dose-dependent stimulation of N13 cells (C) or increase in apoptotic N2a cells (D) was observed
exclusively on sonicated samples. E: Sonication could release Abeta from isolated Abeta plaques. Isolated Abeta plaques were homogenized by either
Dounce or sonication (4 pulses) and the soluble Abeta release, after ultracentrifugation, was assayed by western blots. As shown, sonication solubilized and
released predominantly monomeric and dimeric Abeta. After longer exposures (right panel), other Abeta oligomers, such as trimers or hexamers, could be
also identified.
doi:10.1371/journal.pone.0114041.g002
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based extraction. As expected from previous data, the TBS soluble fraction was
enriched on soluble APPalpha and no Abeta was detected (see Fig. 3A and B for
quantification). However, this TBS-soluble fraction seemed to be contaminated
with cytosolic proteins (detected using LC3-I) and presented low mitochondrial
contamination (ATPsynthase). On the other hand, the Abeta species were
principally accumulated into the intracellular, vesiculated, LC3-II positive fraction
(probably autophagic vesicles, extracted after RIPA treatment) and in plaque
enriched fractions (2% SDS and 4% SDS/8M urea releasable fraction). Thus, these
data demonstrated that the TBS soluble fractions contained extracellular and
cytosolic proteins with low contamination of Abeta plaques.
We have also evaluated to which extent our approach, Dounce homogeniza-
tion, could release the plaque-associated Abeta from tissue. For this experiment,
PS1xAPP cortical samples (12 months of age) were first homogenized, using
Dounce, and ultracentrifuged in order to eliminate all putative soluble Abeta. The
remaining pellets (containing plaques) were subjected to a second round of
homogenization using either Dounce or sonication. Theoretically, all soluble
Abeta species release from this second homogenization should derive from
intracellular vesicles and/or Abeta plaques. As shown in Fig. 3C, Dounce
homogenization did not produce the release of monomeric Abeta whereas
monomeric, dimeric and probably trimeric Abeta were clearly observed after
sonication of the samples.
Discussion
In this work, we demonstrate that different conditions of sample homogenization
profoundly affect the Abeta content in the soluble fractions, probably by inducing
artefactual mobilization of Abeta species from Abeta plaques. We show that using
a mild homogenization protocol (manual Dounce), which is the routine
procedure in our lab, the soluble fractions from both AD brain samples and
PS1xAPP mouse brain tissue contain very small amounts of oligomeric Abeta. In
contrast, when using stronger homogenization methods, such as sonication, large
amounts of Abeta oligomers were found in the soluble fractions.
We first characterized the soluble Abeta content in hippocampal samples
obtained from age-matched non-demented (Braak II, III and IV) and demented
(Braak V and VI) human autopsies. The soluble fractions were prepared using
mild homogenization conditions, followed by ultracentrifugation, as reported
previously [9, 10, 19, 22]. Our data demonstrated the presence of limited amounts
Figure 3. A–B:Biochemical analysis of theDounce-derived soluble fractions.The presence of APPderived fragments, such asAbeta (6E10) and soluble
APPalpha (extracellular), together with LC3-I (cytosolic), ATPsynthase-beta (mitochondrial) and LC3-II (autophagic vesicles) was tested by western blots. A
representative western blot (A) or quantitative analysis of three experiments (B) is shown. Although contaminated with cytosolic proteins (LC3-I), the TBS
soluble fraction was enriched in extracellular soluble APP-alpha and lacked monomeric Abeta. The monomeric Abeta was predominantly concentrated in
vesiculated, LC3-II positive, and plaque associated fractions. C: Dounce homogenization preserved the integrity of Abeta plaques. After a first
homogenization and centrifugation, pellets containing Abeta plaques were re-homogenized using Dounce or sonication (4 pulses) and the soluble Abeta
content assayed using western blots and 6E10. Monomeric Abeta was exclusively observed after sonication.
doi:10.1371/journal.pone.0114041.g003
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of Abeta (pg/mg protein) in the soluble fractions, although we were unable to
identify the nature of the Abeta peptides by either western blots or in
immunoprecipitation assays using 6E10 or OC (not shown) antibodies. Overall,
these data are similar to those reported by some authors [21, 4], but differ from
many others reporting the presence of large amounts of different soluble Abeta
species, specially in human AD samples [3, 13, 14, 16, 17, 24, 23].
These differences could derive, at least in part, from the different brain regions
analyzed and the relative abundance of diffuse versus neuritic Abeta plaques
(hippocampal formation with low or non diffuse plaques, unpublished results,
versus different cortical areas with relatively high proportion of diffuse plaques;
see [13]). However, these conflicting observations could also derive from the
different protocols used in the soluble fraction preparation. This observation
prompted us to investigate the possible effect of the homogenization protocol in
the preparation of soluble fractions and plaque integrity. For this purpose, we
directly compared two approaches broadly used for homogenization and isolation
of soluble Abeta species, manual Dounce homogenization [9, 4, 21] versus
sonication [17, 16]. Using 12-month-old PS1xAPP cortical samples as a source of
abundant Abeta plaques, we demonstrate that Dounce homogenization mostly
preserves the integrity of Abeta plaques and, in consequence, minimizes the level
of contaminating Abeta in soluble fractions, whereas sonication (and probably
other strong homogenization approaches) mechanically disrupts Abeta plaques,
determining a redistribution of monomeric/oligormeric Abeta in all fractions
analyzed. It is particularly relevant the presence of large amounts of Abeta in the
soluble TBS fraction and in the microsomal fractions. These two fractions were
virtually devoid of Abeta when using manual Dounce homogenization (see also
[19]).
A direct consequence of the homogenization method used, is the presence of
varying amounts of oligomeric Abeta which strongly influence the pro-
inflammatory and toxic effects of the soluble fractions, assayed ‘‘in vitro’’. As we
demonstrate in this work, the scarce soluble Abeta, extracted using mild
homogenization, produces no microglial stimulation and no degeneration in
‘‘in vitro’’ assays. On the contrary, the presence of high levels of monomeric and/
or oligomeric species, extracted using sonication, produces clear microglial
stimulation and neuronal degeneration. Thus, as a consequence of a strong initial
tissue homogenization, the soluble TBS fraction could artifactually become pro-
inflammatory and neurotoxic.
It could be argued that the absence of Abeta in the Dounce-homogenized
soluble fractions is due to an incomplete disruption of the tissue and that
sonication could better mobilize the soluble Abeta pool. Although it is possible
that a fraction of the soluble Abeta might indeed remain unextracted in the
Dounce-treated tissue, the redistribution observed after sonication most probably
reflects the disaggregation of the Abeta plaques. This suggestion is based on: i) the
soluble Abeta42 is detected predominantly in samples from demented individuals
(Braak V–VI), whereas similar Abeta40 levels are clearly observed in samples with
few or no Abeta plaques (Braak II), moderate Abeta pathology (Braak III–IV) and
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high pathology (Braak V–VI); ii) as showed (see Fig. 2A), sonication produced a
redistribution of Abeta from 2% SDS or 4% SDS/8M urea fractions (mostly Abeta
plaques) to soluble fractions; iii) we observed a strong effect of sonication
treatment on the integrity of biochemically isolated Abeta plaques. In fact, after
sonication, the Abeta initially forming SDS-resistant aggregates, sedimentable by
ultracentrifugation, is solubilized and redistributed into the TBS fraction. Taken
together, these data demonstrate that isolation of soluble Abeta species is highly
dependent on Abeta plaque preservation, and that the homogenization procedure
is a critical step.
The existence of low levels of Abeta species (below the detection limits of our
assays) in TBS soluble fractions is in agreement with data obtained by others using
microdialysis [7, 8, 20]. In fact, when the brain tissue is not manipulated, the
Abeta levels in the interstitial fluid (ISF) are much lower than that obtained in the
TBS extractable fractions [7, 8]. As we have demonstrated in this work, if the
integrity of Abeta plaques is preserved during homogenization, the levels of
soluble Abeta are very low, below the detection limits of most common
approaches. However, when the Abeta plaques are disturbed, more soluble Abeta
is clearly detected. Thus, the plaques constituted a very large pool of Abeta (either
monomeric or oligomeric) than could be released not only by treatment using
detergents or formic acid but mechanically during homogenization using strong
conditions (such as sonication).
Based on the above data, it could be argued that soluble fractions isolated using
mild (possible low recovery) or strong (partial plaque solubilization) homo-
genization approaches are not representative of the real Abeta content in the
interstitial fluids (see also [8]), and that only microdialysis, using large cutoff
membranes, may better represent the actual Abeta equilibrium in the ISF (see
[20]). However, taken into account that microdialysis is an ‘‘in vivo’’ procedure,
the isolation of soluble fractions is the only approach to analyze postmortem
human tissue. Thus, to characterize the soluble Abeta species from human
samples, special care must be taken in the initial tissue homogenization since, due
to the Abeta plaque instability, a strong homogenization procedure could produce
a vast redistribution of the Abeta species in all soluble and insoluble fractions.
This artifact could explain the dissimilar and somehow controversial data between
different groups analyzing human AD samples.
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